Central Giant Cell Granuloma: A Decade of Institutional Experience and Curative Potential of Neoadjuvant Denosumab
Clicks: 1
ID: 317516
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #118 of 119 articles by views in journal of bone and mineral research : the official journal of the american society for bone and mineral research
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Central giant cell granuloma (CGCG) is a rare lesion of the maxilla and/or mandible affecting young adults. Traditionally, first-line management includes surgery, however surgery portends significant associated risks, including risk of disfigurement, especially given the young age of patients affected and the facial placement of the lesion. Medical therapy has been previously described, however there is uncertainty regarding choice, duration of medical therapy, and risk of recurrence. RANKL inhibition through denosumab has previously been described in a related condition, giant cell tumor of bone, and has been used in central giant cell granuloma in other small case series. Here, we propose the usage of denosumab as a neo-adjuvant treatment prior to surgical resection. We describe a denosumab regimen of 120 mg monthly subcutaneously with a stepwise increase in dosing interval depending on individual clinical, biochemical, and radiological response to treatment, to 2-monthly, 3-monthly, and 6-monthly. Twelve patients were included in this longitudinal study, and clinical and radiologic response was seen in all patients after a mean of 3 and 6 denosumab doses, respectively. Neoadjuvant denosumab use led to complete remission in the majority of cases. Adverse events included hypocalcemia and hypercalcemia, with no cases of medication related osteonecrosis of the jaw. This study demonstrates efficacy of denosumab in the treatment of CGCG both as initial and final treatment and as neo-adjuvant treatment prior to surgical resection.
| Reference Key |
openalex_W7164923957
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Chih Ying Ko, Hedley Coleman, James Kim, Timothy Manzie, Lydia Lim, Joel A. Vanderniet, Yoon Ji Jina Rhou, Christian M. Girgis |
| Journal | journal of bone and mineral research : the official journal of the american society for bone and mineral research |
| Year | 2026 |
| DOI |
10.1093/jbmr/zjag097
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.